The Association of Adherence to Antiretroviral Therapy with Healthcare Utilization and Costs for Medical Care

Overview

Journal Appl Health Econ Health Policy

Specialty Public Health

Date 2009 Feb 24

PMID 19231907

Citations 17

Authors

Edward M Gardner

Moises E Maravi

Cornelis Rietmeijer

Arthur J Davidson

William J Burman

Affiliations

Soon will be listed here.

Abstract

Background: The association between antiretroviral adherence, healthcare utilization and medical costs has not been well studied.

Objective: To examine the relationship of adherence to antiretroviral medications to healthcare utilization and healthcare costs.

Methods: A retrospective cohort study was conducted using data from 325 previously antiretroviral medication-naive HIV-infected individuals initiating first antiretroviral therapy from 1997 through 2003. The setting was an inner-city safety net hospital and HIV clinic in the US. Adherence was assessed using pharmacy refill data. The average wholesale price was used for prescription costs. Healthcare utilization data and medical costs were obtained from the hospital billing database, and differences according to quartile of adherence were compared using analysis of variance (ANOVA). Multivariate logistic regression was used to assess predictors of higher annual medical costs. Sensitivity analyses were used to examine alternative antiretroviral pricing schemes. The perspective was that of the healthcare provider, and costs were in year 2005 values.

Results: In 325 patients followed for a mean (+/- SD) 3.2 (1.9) years, better adherence was associated with lower healthcare utilization but higher total medical costs. Annual non-antiretroviral medical costs were $US 7,612 in the highest adherence quartile versus $US 10,190 in the lowest adherence quartile. However, antiretroviral costs were significantly higher in the highest adherence quartile ($US 17,513 vs $US 8,690), and therefore the total annual medical costs were also significantly higher in the highest versus lowest adherence quartile ($US 25,125 vs $US 18,880). In multivariate analysis, for every 10% increase in adherence, the odds of having annual medical costs in the highest versus lowest quartile increased by 87% (odds ratio 1.87; 95% CI 1.45, 2.40). In sensitivity analyses, very low antiretroviral prices (as seen in resource-limited settings) inverted this relationship - excellent adherence was cost saving.

Conclusion: Better adherence to antiretroviral medication was associated with decreased healthcare utilization and associated costs; however, because of the high cost of antiretroviral therapy, total medical costs were increased. Combination antiretroviral therapy is known to be cost effective; lower antiretroviral costs may make it cost saving as well.

Citing Articles

State of HIV costing in Latin America and the Caribbean: a systematic literature review.

Cerecero-Garcia D, Terris-Prestholt F, Macias-Gonzalez F, Bautista-Arredondo S Rev Panam Salud Publica. 2024; 48:e84.

PMID: 39286659 PMC: 11404235. DOI: 10.26633/RPSP.2024.84.

Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.

Colson A, Chastek B, Gruber J, Majethia S, Zachry W, Mezzio D J Manag Care Spec Pharm. 2024; 30(8):817-824.

PMID: 39088337 PMC: 11294950. DOI: 10.18553/jmcp.2024.30.8.817.

Patients' and Providers' Views on Optimal Evidence-Based and Scalable Interventions for Individuals at High Risk of HIV Treatment Failure: Sequential Explorations Among Key Stakeholders in Cape Town, South Africa.

Sabin L, Gifford A, Haberer J, Harvey K, Sarkisova N, Martin K AIDS Behav. 2022; 26(8):2783-2797.

PMID: 35190943 DOI: 10.1007/s10461-022-03623-7.

A Descriptive Study of HIV Patients Highly Adherent to Antiretroviral.

Williams N, Mayer C, Huser V AMIA Annu Symp Proc. 2021; 2020:1295-1304.

PMID: 33936506 PMC: 8075478.

The Cost-Effectiveness of Adapting and Implementing a Brief Intervention to Target Frequent Alcohol Use Among Persons with HIV in Vietnam.

Blackburn N, Go V, Bui Q, Hutton H, Tampi R, Sripaipan T AIDS Behav. 2021; 25(7):2108-2119.

PMID: 33392969 PMC: 8576395. DOI: 10.1007/s10461-020-03139-y.

References

Bangsberg D, Kroetz D, Deeks S . Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007; 4(2):65-72. DOI: 10.1007/s11904-007-0010-0. View

Keiser P, Nassar N, Kvanli M, Turner D, Smith J, Skiest D . Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J Acquir Immune Defic Syndr. 2001; 27(1):14-9. DOI: 10.1097/00126334-200105010-00003. View

Hogg R, Heath K, Bangsberg D, Yip B, Press N, OShaughnessy M . Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002; 16(7):1051-8. DOI: 10.1097/00002030-200205030-00012. View

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

Mannheimer S, Matts J, Telzak E, Chesney M, Child C, Wu A . Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005; 17(1):10-22. DOI: 10.1080/09540120412331305098. View

Purdum A, Johnson K, Globe D . Comparing total health care costs and treatment patterns of HIV patients in a managed care setting. AIDS Care. 2004; 16(6):767-80. DOI: 10.1080/09540120412331269602. View

Badri M, Maartens G, Mandalia S, Bekker L, Penrod J, Platt R . Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med. 2005; 3(1):e4. PMC: 1298940. DOI: 10.1371/journal.pmed.0030004. View

Freedberg K, Losina E, Weinstein M, Paltiel A, Cohen C, Seage G . The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001; 344(11):824-31. DOI: 10.1056/NEJM200103153441108. View

Kumarasamy N, Vallabhaneni S, Flanigan T, Balakrishnan P, Cecelia A, Carpenter C . Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients. AIDS. 2005; 19(6):625-7. DOI: 10.1097/01.aids.0000163940.85940.03. View

10.

Rietmeijer C, Davidson A, Foster C, Cohn D . Cost of care for patients with human immunodeficiency virus infection. Patterns of utilization and charges in a public health care system. Arch Intern Med. 1993; 153(2):219-25. View

11.

Bangsberg D, Perry S, Charlebois E, Clark R, Roberston M, Zolopa A . Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15(9):1181-3. DOI: 10.1097/00002030-200106150-00015. View

12.

Cantrell C, Eaddy M, Shah M, Regan T, Sokol M . Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006; 44(4):300-3. DOI: 10.1097/01.mlr.0000204287.82701.9b. View

13.

Yazdanpanah Y, Goldie S, Losina E, Weinstein M, Lebrun T, Paltiel A . Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther. 2003; 7(4):257-66. View

14.

Cleary S, McIntyre D, Boulle A . The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis. Cost Eff Resour Alloc. 2006; 4:20. PMC: 1770938. DOI: 10.1186/1478-7547-4-20. View

15.

Miners A, Sabin C, Trueman P, Youle M, Mocroft A, Johnson M . Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med. 2001; 2(1):52-8. DOI: 10.1046/j.1468-1293.2001.00048.x. View

16.

Schackman B, Gebo K, Walensky R, Losina E, Muccio T, Sax P . The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006; 44(11):990-7. DOI: 10.1097/01.mlr.0000228021.89490.2a. View

17.

Wood E, Hogg R, Yip B, Harrigan P, OShaughnessy M, Montaner J . Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?. AIDS. 2003; 17(5):711-20. DOI: 10.1097/00002030-200303280-00009. View

18.

Steinbrook R . Thailand and the compulsory licensing of efavirenz. N Engl J Med. 2007; 356(6):544-6. DOI: 10.1056/NEJMp068297. View

19.

de Assis Acurcio F, Puig-Junoy J, Bonolo P, Ceccato M, Crosland Guimaraes M . [Cost-effectiveness of initial adherence to antiretroviral therapy among HIV infected patients in Belo Horizonte, Brazil]. Rev Esp Salud Publica. 2006; 80(1):41-54. DOI: 10.1590/s1135-57272006000100005. View

20.

Chen R, Accortt N, Westfall A, Mugavero M, Raper J, Cloud G . Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006; 42(7):1003-10. DOI: 10.1086/500453. View